Correction of Hyponatremia by Tolvaptan Before Left Ventricular Assist Device Implantation
-
- Imamura Teruhiko
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Kinugawa Koichiro
- Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo
-
- Shiga Taro
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Kato Naoko
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Endo Miyoko
- Department of Organ Transplantation, Graduate School of Medicine, The University of Tokyo
-
- Inaba Toshiro
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Maki Hisataka
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Hatano Masaru
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Yao Atsushi
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Hirata Yasunobu
- Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
-
- Nishimura Takashi
- Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo
-
- Kyo Shunei
- Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo
-
- Ono Minoru
- Department of Cardiothoracic Surgery, Graduate School of Medicine, The University of Tokyo
-
- Nagai Ryozo
- Jichi Medical University
この論文をさがす
抄録
Hypervolemic hyponatremia is often complicated with advanced heart failure together with increased excretion of sodium by diuretics. Tolvaptan, an oral vasopressin-2-receptor antagonist, has been previously reported to improve congestion and correct hyponatremia through increased excretion of free water. However, there is little evidence concerning the administration of tolvaptan in patients with stage D heart failure. We experienced 2 patients with stage D heart failure who received 3.75 mg/day of tolvaptan to correct hyponatremia before ventricular assist device implantation. It may be useful, even for patients with stage D heart failure, to administer a low dose of tolvaptan to treat hyponatremia before ventricular assist device implantation to avoid a drastic alteration in serum sodium concentration perioperatively.
収録刊行物
-
- International Heart Journal
-
International Heart Journal 53 (6), 391-393, 2012
一般社団法人 インターナショナル・ハート・ジャーナル刊行会